Company intelligence / Profile preview

M6P Therapeutics

St. Louis, Missouri, United Statesm6ptherapeutics.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

The company has presented promising preclinical data for multiple lysosomal storage disorders including Gaucher disease, Pompe disease, and Mucolipidosis type II. They presented data at the 19th Annual WORLD Symposium 2023 and other scientific conferences, showing potential efficacy in their preclinical programs[2][5].

Therapeutic areas: Rare DiseasesNeurologyMetabolic Disorders
Modalities: Enzyme replacement therapyGene therapy
Industry: Biotech

Drug pipeline

13 assets

M041

Preclinical

12 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on M6P Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M6P Therapeutics.

Explore the full profile